In contrast to NSCLC—where receptor tyrosine kinase (RTK) fusions such as ALK, ROS1, and RET are critical biomarkers predicting durable responses to tyrosine kinase inhibitors (TKIs)—the clinical efficacy of TKIs in glioblastoma remains limited. Here, NTRK1 is linked to glioblastoma.